A proposed treatment for erythropoietic protoporphyria has been rejected by the UK body NICE.
Clinuvel Pharmaceuticals announced that the Australian Therapeutic Goods Administration (TGA) has approved the registration of its drug Scenesse (afamelanotide) for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Analyses of a Phase III US study (CUV039) evaluating the administration of Scenesse (afamelanotide), from Clinuvel Pharmaceuticals, to patients diagnosed...
Clinuvel Pharmaceuticals Ltd. has worked for more than a decade to bring Scenesse (afamelanotide) to the US market for the...
Clinuvel Pharmaceuticals Limited announced that its drug Scenesse (afamelanotide 16mg) has been launched in Europe, with the first commercial delivery...
On 23 October 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...